v3.26.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Research and development expenses $ 5,232,541 $ 4,581,672
Acquisition-related costs   419,042
General and administrative expenses 2,297,358 2,016,309
Operating Loss (7,529,899) (7,017,023)
Other (Expense) Income:    
Grant income   252,554
Interest expense (27,974)  
Interest income 21,275 100,098
Total Other (Expense) Income (6,699) 352,652
Net Loss (7,536,598) (6,664,371)
Series A Preferred cash dividend (2,089) (2,089)
Net Loss attributable to common stockholders $ (7,538,687) $ (6,666,460)
Net Loss per share, basic $ (0.13) $ (0.15)
Net Loss per share, diluted $ (0.13) $ (0.15)
Weighted-average shares outstanding, basic 60,010,237 43,404,947
Weighted-average shares outstanding, diluted 60,010,237 43,404,947

Source